Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants Diversity Supplement

COPDGene 参与者的肌肉功能障碍和缺乏活动 5 年进展的决定因素 Diversity Supplement

基本信息

项目摘要

ABSTRACT COVID-19 disease is a highly transmittable viral infection caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2. Rapid human-to-human transmission has forced countries to implement restrictions to reduce the rate and impact of community spread. Advice for social restrictions was especially directed to the elderly and individuals with pre-existing chronic conditions, who are at greater risk of developing severe COVID-19 disease. These restrictions led to many individuals sheltering in their homes, in solitary or household isolation, for weeks or more at a time, affecting their social interactions and increasing poor health behaviors such as binge eating and physical inactivity. Reduced daily physical activity underlies many detrimental facets to health, including but not limited to poor glucose and lipid control, cardiovascular disease, cancer and a pro-inflammatory state. The CDC has identified physical inactivity as an “actual cause” of chronic disease, which contributes to the pathology and progression of many diseases including chronic obstructive pulmonary disease (COPD). COPD is a progressive lung disease that causes breathing difficulties, and, until COVID-19, was the 4th leading cause of death in the USA. In COPD, physical inactivity is associated with muscle dysfunction (e.g., loss of muscle mass, low oxidative capacity and increased oxidative stress) and exercise intolerance. Physical activity and exercise capacity are the strongest predictors of early mortality in COPD, rather than the severity of pulmonary function impairment. Many COPD patients report that the social restrictions imposed to mitigate COVID-19 exacerbated physical inactivity, increased depression and reduced quality-of-life. This study will assess the effect of COVID-19 restrictions on physical activity, symptoms, depression and quality-of-life. Fifty individuals who had these assessments made prior to COVID-19 restrictions in the parent Muscle Health Study (R01HL151452), will repeat these assessments now, after COVID-19 restrictions were implemented. In the past twelve months several studies were published elucidating the characteristics, pathogenesis and acute complications of COVID-19 disease, however the longer-term consequences are still unknown. Future impacts are especially relevant for patients with lung conditions such as COPD who are at greater risk of persistent consequences for at least 6 months after infection (e.g., dyspnea, fatigue, poor mental health, sleep problems). This proposal will provide evidence to support and promote efforts to re-tool pulmonary rehabilitation programs to impart impactful benefits in the COPD patients using virtual formats. Furthermore, this study would pave a career path for Mr. Baez, a Master’s Student at the University of Rhode Island, to pursue his training in respiratory therapy for chronic lung disease patients.
摘要 COVID-19疾病是一种由新型冠状病毒严重急性 呼吸道综合征冠状病毒2.快速的人际传播迫使各国实施 限制,以减少社区传播的速度和影响。特别是对社会限制的建议 针对老年人和患有预先存在的慢性病的人,他们有更大的发展风险, 严重的COVID-19疾病。这些限制导致许多人在家中、单独或 家庭隔离,一次长达数周或更长时间,影响他们的社会交往,并使健康状况恶化 暴饮暴食和缺乏运动等行为。日常体力活动减少是许多 对健康有害的方面,包括但不限于葡萄糖和脂质控制不良,心血管疾病, 癌症和促炎状态。疾病预防控制中心已经确定身体不活动是慢性疾病的“实际原因”。 疾病,这有助于许多疾病的病理和进展,包括慢性阻塞性肺疾病 肺疾病(COPD)。 COPD是一种导致呼吸困难的进行性肺部疾病,在COVID-19之前, 美国的死因。在COPD中,缺乏身体活动与肌肉功能障碍有关(例如,损失 肌肉质量、低氧化能力和增加的氧化应激)和运动不耐受。身体活动 和运动能力是COPD早期死亡率的最强预测因子,而不是COPD的严重程度。 肺功能损害许多COPD患者报告说,为缓解COPD而施加的社会限制 COVID-19加剧了身体活动不足,增加了抑郁症,降低了生活质量。本研究将 评估COVID-19限制对身体活动、症状、抑郁和生活质量的影响。五十 在母体肌肉健康研究中,在COVID-19限制之前进行这些评估的个人 (R 01 HL 151452)将在COVID-19限制措施实施后重复这些评估。 在过去的12个月里,发表了几项研究,阐明了其特征、发病机制和 COVID-19疾病的急性并发症,但长期后果仍未知。未来 影响对于患有肺部疾病的患者尤其相关,例如COPD,他们的风险更大, 感染后至少6个月的持续后果(例如,呼吸困难、疲劳、心理健康状况差、睡眠 问题)。这项提案将提供证据,支持和促进重新装备肺 康复计划,使用虚拟格式为COPD患者带来有影响力的益处。此外,委员会认为, 这项研究将为罗得岛大学的硕士生贝兹先生铺平职业道路, 继续接受为慢性肺病患者进行呼吸治疗的培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Alessandra Adami其他文献

Alessandra Adami的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Alessandra Adami', 18)}}的其他基金

Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants.
COPDGene 参与者肌肉功能障碍和不活动 5 年进展的决定因素。
  • 批准号:
    10339339
  • 财政年份:
    2020
  • 资助金额:
    $ 7.02万
  • 项目类别:
Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants.
COPDGene 参与者肌肉功能障碍和不活动 5 年进展的决定因素。
  • 批准号:
    10552666
  • 财政年份:
    2020
  • 资助金额:
    $ 7.02万
  • 项目类别:
Determinants of 5 Year Progression of Muscle Dysfunction and Inactivity in COPDGene Participants.
COPDGene 参与者肌肉功能障碍和不活动 5 年进展的决定因素。
  • 批准号:
    10542228
  • 财政年份:
    2020
  • 资助金额:
    $ 7.02万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 7.02万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了